Home
/
Allogene Therapeutics, Inc.
/
Financials
/
Quarterly
Allogene Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Allogene Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$0
Aug 13, 2025
Q1
2025
Mar 31, 2025
$0
May 13, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$0
Aug 13, 2025
Q1
2025
Mar 31, 2024
$22.0K
May 13, 2025
Q3
2024
Sep 30, 2023
$22.0K
Nov 7, 2024
Q2
2024
Jun 30, 2023
$22.0K
Aug 7, 2024
Q1
2024
Mar 31, 2023
$30.0K
May 13, 2024
Q3
2023
Sep 30, 2022
$49.0K
Nov 2, 2023
Q2
2023
Jun 30, 2022
$86.0K
Aug 2, 2023
Q1
2023
Mar 31, 2022
$61.0K
May 3, 2023
Q3
2022
Sep 30, 2021
$49.0K
Nov 2, 2022
Q2
2022
Jun 30, 2021
$44.0K
Aug 9, 2022
Q1
2022
Mar 31, 2021
$38.35M
May 4, 2022
Q3
2021
Sep 30, 2020
$0
Nov 4, 2021
Q2
2021
Jun 30, 2020
$0
Aug 4, 2021
Q1
2021
Mar 31, 2020
$0
May 5, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($41.40M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($50.94M)
Aug 13, 2025
Q3
2025
Jun 30, 2025
($50.94M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($59.73M)
May 13, 2025
Q2
2025
Mar 31, 2025
($59.73M)
Aug 13, 2025
Q3
2025
Mar 31, 2025
($59.73M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
($66.29M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
($66.36M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($66.36M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($65.00M)
May 13, 2025
Q2
2025
Mar 31, 2024
($65.00M)
Aug 13, 2025
Q3
2025
Mar 31, 2024
($65.00M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($62.29M)
Nov 7, 2024
Q3
2024
Jun 30, 2023
($79.23M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($79.23M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($99.97M)
May 13, 2024
Q3
2024
Mar 31, 2023
($99.97M)
Nov 7, 2024
Q2
2024
Mar 31, 2023
($99.97M)
Aug 7, 2024
Q3
2023
Sep 30, 2022
($83.15M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($74.79M)
Aug 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($44.90M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($56.82M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($65.19M)
May 13, 2025
Q3
2025
Sep 30, 2024
($71.77M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($71.43M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($69.50M)
May 13, 2025
Q3
2024
Sep 30, 2023
($63.00M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($80.54M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($99.09M)
May 13, 2024
Q3
2023
Sep 30, 2022
($82.49M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($76.59M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($79.99M)
May 3, 2023
Q3
2022
Sep 30, 2021
($77.67M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($71.03M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($33.20M)
May 4, 2022
Q3
2021
Sep 30, 2020
($68.04M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($63.16M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($57.68M)
May 5, 2021
Q3
2020
Sep 30, 2019
($55.01M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($45.96M)
Aug 5, 2020